News

News 14.09.2020 Zurich-Schlieren, Switzerland, September 14, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the completion of initial Good Manufacturing Practice (GMP) manufacturing runs of its tri-specific, antiviral DARPin® candidate for COVID-19, named MP0420....

News 09.09.2020 Schlieren (Zurich), Switzerland, September 9, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, notes the successful initial public offering (IPO) on NASDAQ (NASDAQ: CMPI) of Checkmate Pharmaceuticals, which has licensed CMP-001, formerly known as CYT003, from Kuros. Checkmate raised gross proceeds of $75 million in its recent...

News 01.09.2020 Schlieren (Zurich), Switzerland, September 1, 2020 – Kuros Biosciences, a leader in next generation bone graft technologies, today announced that the first patient has been treated in the STRUCTURE trial, investigating Fibrin-PTH (KUR-113) for transforaminal lumbar interbody fusion (TLIF) procedures in patients with degenerative disc disease. The first patient was...

News 26.08.2020 Research & Development: Developed novel anti-COVID-19 multi-specific DARPin® candidates, of which MP0420 is being prepared for clinical trial initiation in Q4 2020. Initial in vitro and in vivo data highly supportive of unique mechanisms of action with ultra-potent anti-viral activity seen. Secured partnership with AGC Biologics to meet initial projected...

News 14.08.2020 Swiss biotech company Memo Therapeutics AG (MTx) isolated a highly potent antibody isolated from clinically selected convalescent COVID-19 donors. The selected antibody will undergo an accelerated development program as an immunotherapy and for the prevention of COVID-19. MTx has already concluded a partnership for the production. MTx today announces a collaboration...